VEGFC and myocardial infarction: They found that treatment with the VEGF-C/VEGF-D trap (soluble VEGFR3) restricted the recruitment of T cells into the infarcted area, resulting in reduced left ventricular wall thinning, delayed scar remodeling, and reduced cardiac dysfunction after myocardial infarction.